Anti-Frizzled 2 Antibody, Non-Fucosylated (CAT#: BioBet-900ZP) Datasheet

FZD2

frizzled class receptor 10

This intronless gene is a member of the frizzled gene family. Members of this family encode seven-transmembrane domain proteins that are receptors for the wingless type MMTV integration site family of signaling proteins. This gene encodes a protein that is coupled to the beta-catenin canonical signaling pathway. Competition between the wingless-type MMTV integration site family, member 3A and wingless-type MMTV integration site family, member 5A gene products for binding of this protein is thought to regulate the beta-catenin-dependent and-independent pathways.

FZD2; frizzled class receptor 2; Fz2; fz-2; fzE2; hFz2; frizzled-2; frizzled homolog 2; frizzled family receptor 2; frizzled 2, seven transmembrane spanning receptor

Plasma membrane

Diseases associated with FZD2 include Omodysplasia 2 and Robinow Syndrome, Autosomal Dominant 2.

Its related pathways are Regulation of activated PAK-2p34 by proteasome mediated degradation and Association Between Physico-Chemical Features and Toxicity Associated Pathways.

Wnt protein receptor. Most frizzled protein receptors bind to the typical signaling pathway of -catenin, leading to the activation of scatter proteins, the inhibition of GSK-3 kinase, the nuclear accumulation of -catenin, and the activation of Wnt target genes (PubMed: 25759469). A second signaling pathway involving PKC and calcium flux has been found in some family members, but it is not clear whether it represents a unique pathway or whether it can be integrated into the canonical pathway because of Wnt-mediated GSK-3 Kinase inactivation seems to require PKC. Both of these pathways seem to involve interaction with protein g. It may be involved in the formation of tissue morphology and/or the transduction of polarity information and cell-to-cell transmission in differentiated tissues.

Cancer antibody; Developmental Biology antibody; Signaling Transduction antibody

Ubiquitinated by ZNRF3, leading to its degradation by the proteasome.

Protein Based Therapies
Monoclonal antibody (mAb)

IgG

BioBet-900ZP

Humanized

Human

The antibody specifically bind Fzd2, and may promote internalization of the Fzd2 receptor by the cancer cells and/or prevent ligand binding to Fzd2. It is used for treatment of specific cancers such as late stage hepatocellular carcinoma.

Cancer

Cancer